

Evaluation of the reactivity and receptor competition of HLA-G isoforms toward available antibodies: Implications of structural characteristics of HLA-G isoforms

メタデータ	言語: eng 出版者: 公開日: 2022-09-12 キーワード (Ja): キーワード (En): 作成者: メールアドレス: 所属:
URL	https://doi.org/10.24517/00067079

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 International License.





Article

Evaluation of the Reactivity and Receptor Competition of HLA-G Isoforms toward Available Antibodies: Implications of Structural Characteristics of HLA-G Isoforms

Atsushi Furukawa ^{1,†}, Manami Meguro ^{1,†}, Rika Yamazaki ¹, Hiroshi Watanabe ¹,
Ami Takahashi ¹, Kimiko Kuroki ¹ and Katsumi Maenaka ^{1,2,*}

¹ Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan; afuru@pharm.hokudai.ac.jp (A.F.); manami.meg@frontier.hokudai.ac.jp (M.M.); rika@pharm.hokudai.ac.jp (R.Y.); watanabe_2896@eis.hokudai.ac.jp (H.W.); ami.takahashi@frontier.hokudai.ac.jp (A.T.); k-kimiko@pharm.hokudai.ac.jp (K.K.)

² Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

* Correspondence: maenaka@pharm.hokudai.ac.jp; Tel.: +81-011-706-3970

† These authors contribute equally to this work.

Received: 24 September 2019; Accepted: 22 November 2019; Published: 26 November 2019



Abstract: The human leucocyte antigen (HLA)-G, which consists of seven splice variants, is a tolerogenic immune checkpoint molecule. It plays an important role in the protection of the fetus from the maternal immune response by binding to inhibitory receptors, including leukocyte Ig-like receptors (LILRs). Recent studies have also revealed that HLA-G is involved in the progression of cancer cells and the protection from autoimmune diseases. In contrast to its well characterized isoform, HLA-G1, the binding activities of other major HLA-G isoforms, such as HLA-G2, toward available anti-HLA-G antibodies are only partially understood. Here, we investigate the binding specificities of anti-HLA-G antibodies by using surface plasmon resonance. MEM-G9 and G233 showed strong affinities to HLA-G1, with a nM range for their dissociation constants, but did not show affinities to HLA-G2. The disulfide-linker HLA-G1 dimer further exhibited significant avidity effects. On the other hand, 4H84 and MEM-G1, which can be used for the Western blotting of HLA-G isoforms, can bind to native HLA-G2, while MEM-G9 and G233 cannot. These results reveal that HLA-G2 has a partially intrinsically disordered structure. Furthermore, MEM-G1, but not 4H84, competes with the LILRB2 binding of HLA-G2. These results provide novel insight into the functional characterization of HLA-G isoforms and their detection systems.

Keywords: immune checkpoint; HLA-G; antibody; ELISA

1. Introduction

Human leucocyte antigen (HLA)-G is one of the non-classical major histocompatibility complex-I (MHC-I) molecules, a group that includes HLA-E and HLA-F [1]. Unlike classical MHC-I molecules, HLA-G shows restricted tissues expression, such as in the placenta, and some regulatory T cells [2,3]. HLA-G is reportedly not involved in the antigen presentation for stimulating the immune system but binds inhibitory leukocyte immunoglobulin-like receptors (LILR) molecules to suppress immune activation [4]. In the placenta, HLA-G plays a redundant role in the protection of the fetus from maternal immune responses. Notably, the amounts of HLA-G inversely correlate with the severity of autoimmune diseases [5–7]. We also demonstrated that the administration of the HLA-G molecule

improved the symptoms of the collagen induced arthritis model mice and the atopic dermatitis model mice [8–10]. Furthermore, certain tumor cells also express HLA-G on the surface to suppress immune activation and escape immune surveillance [11,12]. Recent studies have exhibited the importance of the interactions of immune checkpoint inhibitory receptors with cognate ligands, such as program cell death protein 1 (PD-1) and PD-1Ls, and cytotoxic cell lymphocyte antigen-4 (CTLA-4) and CD80/CD86 interactions for cancer therapy [13–15]. Therefore, HLA-G is a prominent drug candidate for autoimmune diseases, and HLA-Gs-LILR interactions are also one of the targets for cancer immune therapy.

HLA-G comprises seven isoforms (HLA-G1 to G7), which harbor different combinations of $\alpha 1$, $\alpha 2$, and $\alpha 3$ domains of heavy chain and $\beta 2$ -microglobulin ($\beta 2m$) in extracellular regions, together with the transmembrane and cytoplasmic domain [16]. HLA-G1 is a well characterized molecule among HLA-Gs, and its ectodomain consists of $\alpha 1$ - $\alpha 2$ - $\alpha 3$ domains, $\beta 2m$, and a peptide. HLA-G2 also has a membrane-anchoring form and contains only two domains, $\alpha 1$ and $\alpha 3$, with a heavy chain in the extracellular region. Our recent biochemical and electron microscopic studies revealed that the ectodomain of HLA-G2 forms a homodimer via non-covalent interactions and strongly binds to LILRB2 [9,17]. Furthermore, HLA-G2 is considered to play an important role in humans who cannot produce functional HLA-G1 due to an HLA-G-null allele [18,19]. HoWangYin et al. demonstrated that the Fc-fusion version of HLA-G2 can prolong the survival of a mouse with skin allografts [20]. We also showed that HLA-G2 has a significant therapeutic effect against arthritis model mice [9]. HLA-G3 and HLA-G4 are predicted to be expressed in membrane-anchoring forms, and contain only single $\alpha 1$ domain and $\alpha 1$ - $\alpha 2$ domains, respectively. HLA-G5, G6, and G7 are soluble forms (non-membrane-anchoring forms) of HLA-G1, G2, and G4, respectively [21]. In addition, the HLA-G1 molecule forms the disulfide-linked HLA-G1 homodimer, which reportedly plays an important role in immune suppression [22,23]. The structural complexity of HLA-G still makes it difficult to precisely evaluate the amount and function of each isoform in vivo. In order to measure HLA-G molecules in the serum of autoimmune and cancer patients, enzyme linked immunosorbent assays (ELISAs) were developed using monoclonal antibodies against HLA-G [24]. MEM-G9 and G233 are widely used in HLA-G ELISA as a capture antibody [25]. MEM-G9 reportedly binds surface expressed HLA-G1 but not HLA-G2, G3, or G4 [26]. Furthermore, the other HLA-G antibody, 4H84, binds denatured or $\beta 2m$ -free HLA-G proteins and is considered to be a useful antibody due to its reactivity in Western blotting against all HLA-G isoforms containing the $\alpha 1$ domain [27–31]. MEM-G1 is also a well-known HLA-G antibody and is reported to recognize the denatured form of the HLA-G protein [32]. However, the molecular specificities of the antibodies against each splice variant and the dimer/monomers of HLA-G remain unclear.

Here, we investigate the reactivities of HLA-G antibodies to HLA-G1 and HLA-G5 (hereafter referred to as HLA-G1 because they have essentially identical ectodomains), and HLA-G2 and HLA-G6 (hereafter referred to as HLA-G2 because they have essentially identical ectodomains). The 4H84 and MEM-G1 are bound to native HLA-G2, not to HLA-G1. Since 4H84 and MEM-G1 can be used for Western blotting, thus indicating that they can recognize denatured HLA-G proteins, HLA-G2 presumably has an unstructured part that is reactive to antibodies. Interestingly, 4H84 can bind to LILRB2-captured HLA-G2, suggesting that the binding sites for 4H84 and LILRB2 are located at sufficiently far distances. This result also suggests the possibility that the combination of 4H84 and LILRB2 enable the development of a sandwich ELISA useful for detection of HLA-G2 and related isoforms. Our biophysical analyses using antibodies revealed the structural features and predicted the ligand binding site of the HLA-G isoforms.

2. Results

2.1. A Surface Plasmon Resonance (SPR) Analysis of Antibody Binding Towards HLA-G1 and Its Disulfide-Linked Dimer

In order to evaluate the binding ability of the antibodies against native HLA-G1 and its homodimer, we performed an SPR analysis. 3.1–50 nM of HLA-G proteins were injected over the antibodies immobilized on a CM5 chip by the amine coupling method (Figure S1A). MEM-G9 and G233 were bound to the HLA-G1 monomer, while the 4H84 and MEM-G1 antibodies did not show any detectable binding at a concentration up to 50 nM (Figure S1A).

A one to one fitting model was applied to kinetics curve of the interaction of MEM-G9 and G233 with the HLA-G1 monomer, successfully determining the K_{d} s of 15.1 ± 0.91 nM (global fitting, χ^2 value is 0.05) and 13.2 ± 0.56 nM (global fitting, χ^2 value is 0.31), respectively (Figure 1A,B).




Figure 1. The surface plasmon resonance (SPR) of human leukocyte antigen (HLA)-G1 monomer, dimer, and HLA-G2 against each immobilized antibody: (A) 12.5–100 nM of the HLA-G1 monomer was injected against the immobilized MEM-G9, and (B) G233, respectively; (C) 6.25–100 nM HLA-G1 dimer was injected against the immobilized MEM-G9, and (D) G233, respectively; (E) 0.23–7.2 nM of HLA-G2 was injected against the immobilized 4H84; (F) 4.5–72 nM HLA-G2 was injected against the immobilized MEM-G1. The subtraction data of IgG control as the negative control are shown. Dash lines are the fitting curve of 1:1 binding model.

Our previous study revealed that the dimer of HLA-G1, rather than the monomer, plays an important role in immune suppression via the avidity effect [23]. In order to investigate the reactivity of antibodies against the HLA-G1 dimer, the HLA-G1 dimer was injected into the immobilized antibody (Figure S1B). Similar to the reactivities against HLA-G1 monomer described above, MEM-G9 and G233 bound to the HLA-G1 dimer. The kinetic analysis revealed that ka_1 , kd_1 , ka_2 , and kd_2 of the interactions of the HLA-G1 dimer with MEM-G9 were determined as 1.54×10^5 (1/Ms), 4.21×10^{-4} (1/s), 1.59×10^{-4} (1/RUs), and 4.36×10^{-6} (1/s), respectively. The ka_1 , kd_1 , ka_2 , and kd_2 of the interactions of the HLA-G1 dimer with G233 were also determined as 1.67×10^5 (1/M·s), 8.24×10^{-5} (1/s), 7.94×10^{-4} (1/RU·s), and 2.58×10^{-2} (1/s), respectively. Apparent dissociation constants of the interaction of HLA-G1 dimer with MEM-G9 and G233 by using 1:1 binding model were 2.45 ± 0.32 nM (global fitting, χ^2 value is 0.02) and 0.77 ± 0.11 nM (global fitting, χ^2 value is 0.29), respectively (Figure 1C,D).

2.2. Western Blotting and SPR Interaction Analyses of HLA-G2 Using the Antibodies

Previous studies demonstrated that MEM-G9 and G233 recognize native HLA-G proteins. In contrast, 4H84 and MEM-G1 recognize the denatured forms [26,27,33,34]. Here, we performed a Western blotting analysis on HLA-G1 and -G2 molecules. Figure 2 shows that both 4H84 and MEM-G1 have specific bands against HLA-G1, as well as HLA-G2, which does not contain the $\alpha 2$ domain, while MEM-G9 and G233 do not have such bands (data not shown). This result reveals that 4H84 and MEM-G1 recognize the sequential epitopes of either the $\alpha 1$ or $\alpha 3$ domains. Indeed, the 4H84 antibody was prepared by immunization using the synthetic peptide, DSDSACPRMEPRAPWVEQEGPEY, corresponding to a part (residues 61 to 83) of the HLA-G $\alpha 1$ domain. On the other hand, MEM-G1 was established via the immunization of the HLA-G1 extracellular domain, and its epitopes have not yet been determined. Consistently, SPR analysis demonstrated that, while HLA-G2 did not bind to MEM-G9 or G233, HLA-G2 showed specific and strong binding to 4H84 and MEM-G1 (Figure 1E,F and Figure S1C). These SPR and Western Blotting analyses suggest that the HLA-G2 molecule has an exposed and flexible part, which can be detectable for 4H84 and MEM-G1.




Figure 2. Coomassie brilliant blue (CBB) staining and Western blot analysis reacted with 4H84 and MEM-G1 of the HLA-G1 monomer and HLA-G2. The HLA-G1 monomer (G1), HLA-G2 (G2), and $\beta 2m$, as a negative control protein (CP), were separated by Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in a reducing condition.

2.3. The Competition Assay for the LILR Receptor Binding of HLA-G Isoforms with Anti-HLA-G Antibodies

In order to further evaluate the antibody binding of HLA-G isoforms, we performed competition assays using the cognate receptors, LILRBs. The schematic images of the competition assays are shown in Figure 3A,D. The HLA-G1 dimer was injected into MEM-G9 or the G233 immobilized chip (Figure S2A). Then, LILRB1 was injected over the HLA-G1 dimer immobilized on the antibodies, showing that the

LILRB1 bound HLA-G1 dimers were immobilized in both antibodies with concentration dependency (Figure 3B). The K_d values of the interaction between the LILRB1 and HLA-G1 dimers immobilized by MEM-G9 (1.5 μM) and G233 (2.5 μM) were similar to those of the interaction between LILRB1 and the immobilized HLA-G1 dimer (2.1 μM), as previously described (Figure 3C) [23]. These results indicate that the recognition site on HLA-G1 of LILRB1 is distinct from the epitopes of MEM-G9 and G233 (Figure 4A).




Figure 3. The competition assays of the MEM-G9 and G233 antibodies with leukocyte immunoglobulin-like receptor (LILR) B1, or 4H84 and MEM-G1 antibodies with LILRB2, using SPR. (A) Schematic image of the competition assay of the MEM-G9 and G233 antibodies with LILRB1. Yellow, pink, green and blue filled circles of HLA-G1 represent the domain $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\beta 2m$, respectively. (B) The sensorgram of LILRB1 injection (0.8–12.5 μM) against HLA-G1 immobilized by MEM-G9 (solid line) and G233 (dot line), with subtraction of the negative control (unimmobilized lane), are shown. (C) Equilibrium binding analysis of MEM-G9 (closed circle) and G233 (closed square). Solid lines represent nonlinear one to one fit for the Langmuir binding isotherm of each plot. (D) Schematic image of the competition assay of 4H84 and MEM-G1 antibodies with LILRB2. Yellow and green filled circles of HLA-G2 represent the domain $\alpha 1$ and $\alpha 3$, respectively. (E) The sensorgram of the continuous injection of 3.1–50 nM of 4H84 (solid line) and MEM-G1 (dot line) into the HLA-G2 immobilized by LILRB2, with subtraction of the negative control (HLA-G2 unimmobilized lane) are shown.

For the HLA-G2 competition assay, first, HLA-G2 was injected over the immobilized LILRB2 (Figure S2B). HLA-G2 was successfully immobilized with significant slow dissociation, indicating a remarkable avidity effect. MEM-G1 and 4H84 were injected over the HLA-G2 immobilized on LILRB2. MEM-G1 did not bind to LILRB2-captured HLA-G2, but 4H84 was bound (Figure 3E). These results revealed that the two antibodies have distinctly different epitopes compared to HLA-G2. Furthermore, this result suggests the possibility that the LILRB2-immobilized chip or well combined with 4H84 as a detection antibody could be utilized in a sandwich ELISA for HLA-G2.




Figure 4. Schematic image of the epitopes of putative HLA-G antibodies and receptor ligand binding site of HLA-G isoforms. (A) The HLA-G1 binding site of MEM-G9 and G233 are not overlapped with those of LILRB1. (B) The binding site of MEM-G1, but not 4H84 on the HLA-G2 homodimer, is overlapped with that of LILRB2.

3. Discussion

In this study, we showed that MEM-G9 and G233 bind to native HLA-G1 molecules but not to denatured HLA-G1 molecules or both the native and denatured forms of HLA-G2. In contrast, 4H84 and MEM-G1 bound to native HLA-G2, as well as the denatured forms of HLA-G1 and HLA-G2.

One of the well characterized antibodies, MEM-G9, was developed against the human recombinant full length HLA-G1 protein [35]. Previous analyses indicated that MEM-G9 recognizes HLA-G1 expressing cells but has no binding activity to HLA-G2 expressing cells [26,27], which is consistent with our current study. In contrast, Pela et al. recently reported that immobilized native HLA-G2 was detected by MEM-G9 but not by MEM-G1 in ELISA, while the denatured HLA-G2 was bound to MEM-G1 but not to MEM-G9 [36]. They prepared HLA-G2 by the on-column refolding method, which is different from our procedure, and did not check any receptor-binding activities or structural characterization. On the other hand, the recombinant HLA-G2 prepared here has a functionally active form, which has the ability to bind to the receptors LILRB2 and the paired Ig-like receptor B (PIR-B), which is the mouse homolog of LILRB2 [9,17].

Moreover, our previous reports showed that HLA-G2 has an immune suppressive effect on collagen induced arthritis and atopic dermatitis-like skin model mice. [9,10]. Furthermore, Meiner et al. showed that HLA-G2 expressing cells bind to 4H84 but not to MEM-G9 [26], which is consistent with our present observations. 4H84 reportedly bound to the denatured form of the $\alpha1$ domain of HLA-G1 by a mild acid treatment [37]. This result is consistent with the present Western blotting analysis, demonstrating that 4H84 bound to the denatured HLA-G isoforms. Notably, SPR analysis showed that 4H84 also bound to native HLA-G2. Indeed, 4H84 was produced by immunization of the peptide, which corresponds to 61–83 amino acid residues in the $\alpha1$ domain of HLA-G isoforms [33]. The crystal

structures of HLA-G1 revealed that these amino acid residues consist of an α helix, which contributes to the peptide binding together with α helix from the $\alpha 2$ domain [33]. In contrast, HLA-G2 does not include the $\alpha 2$ domain, and it is uncertain whether HLA-G2 has a binding ability towards peptides or any small molecules. Our previous structural analysis via electron microscope indicated that HLA-G2 has a relatively less homogenous structure with multiple conformations of the $\alpha 3$ domains, which might be caused by the flexible structure of the $\alpha 1$ domain [17]. Taken together, we propose that the $\alpha 1$ domain of HLA-G2 contains the flexible portion. On the other hand, the competition assay showed that the LILRB2 binding site of HLA-G2 overlaps with MEM-G1 but not 4H84, whose epitopes were not overlapped [28,31]. This result seems consistent with the idea we previously proposed, that the part of the $\alpha 3$ domain of HLA-G2 that faces $\beta 2m$, when bound in the case of HLA-G1, is possibly involved in LILRB2 binding (Figure 4B) [17].

HLA-G is reportedly expressed in many types of cancer cells and involved in metastases [38]. Expression of the tolerogenic HLA-G molecule is considered to confer cancer cells to induce survival environment by suppressing the activation of immune cells. The importance of HLA-G1 molecules in cancer cells has become gradually understood. In contrast, other isoforms, such as HLA-G2, are still unclear [11]. This is due to the limited information on the specificity of HLA-G antibodies against each HLA-G isotype [11]. In this study, we found that the antibodies, 4H84 and MEM-G1, can detect native HLA-G2 but not native HLA-G1. Recently, immune checkpoint inhibitors, which block the interaction between the immune checkpoint receptor and its ligands, have become promising cancer therapeutic agents. Our competition assay revealed that MEM-G1 can block the interaction between HLA-G2 and LILRB2. Therefore, MEM-G1 could be a potential immune checkpoint inhibitor against the interaction between HLA-G2 and LILRB2.

In order to measure HLA-G molecules in autoimmune and cancer patients, HLA-G specific ELISAs were developed using monoclonal antibodies against HLA-G [24]. The antibodies MEM-G9 and G233 are widely used in HLA-G ELISA as a capture antibody [25]. Our SPR analysis revealed that ELISAs using MEM-G9/G233 are suitable for the detection of HLA-G1 molecules. In addition, it was also reported that an ELISA using a combination of antibodies 4H84 and MEM-G1 were suitable for the detection of soluble HLA-G [28]. Our present SPR analysis revealed that HLA-G2, not HLA-G1, molecules can be measured by ELISA using 4H84 and MEM-G1. This result suggests that these antibodies are useful for further functional analysis, as well as the determination of the precise amount of HLA-G2 molecules in vivo. Furthermore, our SPR competition assay revealed that 4H84 bound LILRB2-captured HLA-G2. Therefore, LILRB2, which is detectable for HLA-G2 and related isoforms, is a candidate protein for the capture molecule (instead of antibodies) in the development of ELISA.

In conclusion, we investigated the binding properties of the HLA-G antibodies MEM-G9, MEM-G1, G233, and 4H84 to an HLA-G1 dimer/monomer and HLA-G2. Furthermore, we performed competition experiments for the binding of the LILR receptor. These results provide important insight into the structural features of the HLA-G isotype and the quantitation of HLA-G isoforms for clinical diagnosis and therapy.

4. Materials and Methods

4.1. Antibodies

Commercially available anti-HLA-G monoclonal antibodies, MEM-G1 (IgG1), MEM-G9 (IgG1), G233 (IgG2a), and 4H84 (IgG1), from Abcam, were used in this study to characterize their binding activities to the HLA-G1 monomer and dimer and HLA-G2 (<https://www.abcam.co.jp>).

4.2. Production of the Ectodomains of HLA-G1 (Monomer/Dimer), HLA-G2, and LILRB Receptors

We previously reported the structures (either x-ray crystallography or electron microscopy) and receptor binding activities of the recombinant proteins used in this study were reported previously [9,17,23,39–41]. The HLA-G1 monomer and dimer, and HLA-G2, were produced by the

same methods previously described [8,23,40]. Briefly, for HLA-G1 production, the $\alpha 1$ - $\alpha 2$ - $\alpha 3$ domains of the HLA-G heavy chain were expressed as the inclusion body in *Escherichia coli*. After washing the inclusion body, the HLA-G's heavy chains were refolded together with $\beta 2m$ and a peptide (RIIPRHLQL) via the dilution method. The refolded HLA-G1 was purified by gel filtration (Superdex75 26/60, GE) followed by anion exchange chromatography (Resource Q, GE) in the monomer form. The formation of the disulfide-bonded HLA-G1 dimer was proceeded by incubation of the purified HLA-G1 monomer (10 mg/mL), with 5 mM dithiothreitol (DTT) for 4 days at 4 °C. Finally, the HLA-G dimer was purified by gel filtration chromatography (Superdex 200 10/300, GE). For HLA-G2 production, the HLA-G2 ectodomain (the $\alpha 1$ and $\alpha 3$ domains of the heavy chain) was expressed as an inclusion body of *E. coli*, refolded by the dilution method and purified by gel filtration, similar to HLA-G1 proteins. LILRB1 and biotinylated LILRB2 were also prepared by the same method previously described [23,42]. Briefly, N-terminal domains 1 and 2 of the extracellular domain of the LILR proteins were expressed as the inclusion body of *E. coli*, refolded by the dilution method and purified by gel filtration and anion exchange columns (Resource Q, GE).

4.3. SPR Analysis

Surface plasmon resonance (SPR) experiments were performed with Biacore T200 (GE). Then, 3.1–50 nM of the HLA-G1 monomer, dimer, or HLA-G2 proteins in HBS-EP were continuously injected over the immobilized antibodies and $\beta 2m$ (negative control), with a 10 $\mu\text{L}/\text{min}$ flow rate. For the determination of the dissociation constant, 12.5–100 nM of HLA-G1 monomer and 6.25–100 nM of HLA-G1 dimer were injected against immobilized MEM-G9 and G233 and, 0.23–7.2 and 4.5–72 nM of HLA-G2 were injected against immobilized 4H84 and MEM-G1, respectively, with a 30 $\mu\text{L}/\text{min}$ flow rate. The subtraction data of Ig control as the negative control were used for the calculation of kinetic parameters by bivalent and 1:1 fitting model. Dissociation constants were shown as average \pm standard deviation of triplicate analyses.

The competition experiment was performed with the following procedures. For the HLA-G1 protein competition assay, MEM-G9 and G233 were immobilized on a CM5 chip. HLA-G1 was injected into the antibody immobilized lanes, followed by the injection of 0.8–12.5 μM of LILRB1. The dissociation constant between LILRB1 and the antibody immobilized HLA-G1 was determined by the equilibrium binding analysis previously described [23]. For HLA-G2, the biotinylated LILRB2 was immobilized. Next, HLA-G2 was injected and captured. In total, 3.1–50 nM of 4H84 and MEM-G1 were injected over HLA-G2 on immobilized LILRB2.

4.4. Western Blotting

HLA-G1 and HLA-G2 were fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under a reducing condition and blotted against a nitro cellulose membrane. The 4H84 and MEM-G1 antibodies were used as primary antibodies, and an anti-mouse Fc with horse radish peroxidase (HRP) was used for the secondary antibodies.

Supplementary Materials: The following are available at <http://www.mdpi.com/1422-0067/20/23/5947/s1>, Figure S1: Single cycle analysis of SPR of HLA-G1 monomer, dimer and HLA-G2 against immobilized each antibody. (A) HLA-G1 monomer and (B) HLA-G1 dimer from 3.1 nM to 50 nM continuously injected against immobilized G233 (bold line), MEM-G9 (dot line), MEM-G1 (solid line) and 4H84 (solid line). (C) HLA-G2 from 3.1 nM to 50 nM continuously injected against immobilized 4H84 (bold line), MEM-G1 (dot line), G233 (solid line) and MEM-G9 (solid line), Figure S2: Related to Figure 3 (A) and (C). (A) 100 nM of HLA-G1 dimer was injected against either MEM-G9 (black solid line), G233 (grey solid line) or $\beta 2m$ (black dot line, as a native control) immobilized on flow cell of Biacore CM5 chip with 5 $\mu\text{L}/\text{min}$ for 6 min. (B) 100 nM of HLA-G2 was injected against LILRB2 immobilized on flow cell with 5 $\mu\text{L}/\text{min}$ for 10 min. The sensor gram of the injection of HLA-G2 against LILRB2 in advance of the injection of the antibody is shown in Figure 3C.

Author Contributions: Conceptualization, A.F. and K.M.; data curation, A.F., M.M., R.Y., H.W., and A.T.; formal analysis, A.F., M.M., K.K., and K.M.; supervision, K.M.; writing—original draft, A.F. and M.M.; writing—review and editing, K.K. and K.M.

Funding: This research is supported in part by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research KAKENHI (Grants 22121007), JSPS Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (no. S2701), Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number 18am0101093j0002, Hokkaido University, the Global Facility Center (GFC), the Pharma Science Open Unit (PSOU), funded by the Ministry of Education, Science, Sports, Culture and Technology under the “Support Program for Implementation of New Equipment Sharing System”, Hokkaido University Biosurface project and Takeda Science Foundation.

Acknowledgments: We appreciate Sayaka Niizuma for her technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

β2m	β2-microglobulin
CTLA-4	cytotoxic cell lymphocyte antigen-4
DTT	Dithiothreitol
ELISA	enzyme linked immunosolvent assay
HLA	Human Leucocyte antigen
HRP	horseradish peroxidase
LILR	Leukocyte immunoglobulin-like receptors
MHC	Main Histocompatibility Complex
PD-1	programed cell death protein-1
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
SPR	Surface Plasmon Resonance

References

1. Foroni, I.; Couto, A.R.; Bettencourt, B.F.; Santos, M.; Lima, M.; Bruges-Armas, J. HLA-E, HLA-F and HLA-G—the non-classical side of the MHC cluster. *HLA Assoc. Important Dis.* **2014**, *3*, 61–109. [[CrossRef](#)]
2. Feger, U.; Tolosa, E.; Huang, Y.H.; Waschbisch, A.; Biedermann, T.; Melms, A.; Wiendl, H. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. *Blood* **2007**, *110*, 568–577. [[CrossRef](#)]
3. Rouas-Freiss, N.; Gonçalves, R.M.; Menier, C.; Dausset, J.; Carosella, E.D. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytotoxicity. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 11520–11525. [[CrossRef](#)]
4. Rajagopalan, S.; Long, E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. *J. Exp. Med.* **1999**, *189*, 1093–1100. [[CrossRef](#)]
5. Rizzo, R.; Bortolotti, D.; Bolzani, S.; Fainardi, E. HLA-G Molecules in Autoimmune Diseases and Infections. *Front. Immunol.* **2014**, *5*, 592. [[CrossRef](#)]
6. Verbruggen, L.A.; Rebmann, V.; Demanet, C.; De Cock, S.; Grosse-Wilde, H. Soluble HLA-G in rheumatoid arthritis. *Hum. Immunol.* **2006**, *67*, 561–567. [[CrossRef](#)]
7. Prigione, I.; Penco, F.; Martini, A.; Gattorno, M.; Pistoia, V.; Morandi, F. HLA-G and HLA-E in patients with juvenile idiopathic arthritis. *Rheumatology (Oxford)* **2011**, *50*, 966–972. [[CrossRef](#)]
8. Kuroki, K.; Hirose, K.; Okabe, Y.; Fukunaga, Y.; Takahashi, A.; Shiroishi, M.; Kajikawa, M.; Tabata, S.; Nakamura, S.; Takai, T.; et al. The long-term immunosuppressive effects of disulfide-linked HLA-G dimer in mice with collagen-induced arthritis. *Hum. Immunol.* **2013**, *74*, 433–438. [[CrossRef](#)]
9. Takahashi, A.; Kuroki, K.; Okabe, Y.; Kasai, Y.; Matsumoto, N.; Yamada, C.; Takai, T.; Ose, T.; Kon, S.; Matsuda, T.; et al. The immunosuppressive effect of domain-deleted dimer of HLA-G2 isoform in collagen-induced arthritis mice. *Hum. Immunol.* **2016**. [[CrossRef](#)]
10. Maeda, N.; Yamada, C.; Takahashi, A.; Kuroki, K.; Maenaka, K. Therapeutic application of human leukocyte antigen-G1 improves atopic dermatitis-like skin lesions in mice. *Int. Immunopharmacol.* **2017**, *50*, 202–207. [[CrossRef](#)]
11. Amiot, L.; Ferrone, S.; Grosse-Wilde, H.; Seliger, B. Biology of HLA-G in cancer: A candidate molecule for therapeutic intervention? *Cell Mol. Life Sci.* **2011**, *68*, 417–431. [[CrossRef](#)]

12. Paul, P.; Rouas-Freiss, N.; Khalil-Daher, I.; Moreau, P.; Riteau, B.; Le Gal, F.A.; Avril, M.F.; Dausset, J.; Guillet, J.G.; Carosella, E.D. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 4510–4515. [[CrossRef](#)]
13. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. *Nat. Rev. Cancer* **2012**, *12*, 252–264. [[CrossRef](#)]
14. Walker, L.S.; Sansom, D.M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. *Nat. Rev. Immunol.* **2011**, *11*, 852–863. [[CrossRef](#)]
15. Agaugué, S.; Carosella, E.D.; Rouas-Freiss, N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. *Blood* **2011**, *117*, 7021–7031. [[CrossRef](#)]
16. Carosella, E.D.; Rouas-Freiss, N.; Tronik-Le Roux, D.; Moreau, P.; LeMaoult, J. HLA-G: An Immune Checkpoint Molecule. *Adv. Immunol.* **2015**, *127*, 33–144.
17. Kuroki, K.; Mio, K.; Takahashi, A.; Matsubara, H.; Kasai, Y.; Manaka, S.; Kikkawa, M.; Hamada, D.; Sato, C.; Maenaka, K. Cutting Edge: Class II-like Structural Features and Strong Receptor Binding of the Nonclassical HLA-G2 Isoform Homodimer. *J. Immunol.* **2017**, *198*, 3399–3403. [[CrossRef](#)]
18. Menier, C.; Riteau, B.; Dausset, J.; Carosella, E.D.; Rouas-Freiss, N. HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival. *Hum. Immunol.* **2000**, *61*, 1118–1125. [[CrossRef](#)]
19. Casro, M.J.; Morales, P.; Rojo-Amigo, R.; Martinez-Laso, J.; Allende, L.; Varela, P.; Garcia-Berciano, M.; Guillen-Perales, J.; Arnaiz-Villena, A. Homozygous HLA-G*0105N healthy individuals indicate that membrane-anchored HLA-G1 molecule is not necessary for survival. *Tissue Antigens* **2000**, *56*, 232–239. [[CrossRef](#)]
20. HoWangYin, K.Y.; Loustau, M.; Wu, J.; Alegre, E.; Daouya, M.; Caumartin, J.; Sousa, S.; Horuzsko, A.; Carosella, E.D.; LeMaoult, J. Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. *Cell Mol. Life Sci.* **2012**, *69*, 4041–4049. [[CrossRef](#)]
21. Paul, P.; Cabestre, F.A.; Ibrahim, E.C.; Lefebvre, S.; Khalil-Daher, I.; Vazeux, G.; Quiles, R.M.; Bermond, F.; Dausset, J.; Carosella, E.D. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. *Hum. Immunol.* **2000**, *61*, 1138–1149. [[CrossRef](#)]
22. Boyson, J.E.; Erskine, R.; Whitman, M.C.; Chiu, M.; Lau, J.M.; Koopman, L.A.; Valter, M.M.; Angelisova, P.; Horejsi, V.; Strominger, J.L. Disulfide bond-mediated dimerization of HLA-G on the cell surface. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 16180–16185. [[CrossRef](#)] [[PubMed](#)]
23. Shiroishi, M.; Kuroki, K.; Ose, T.; Rasubala, L.; Shiratori, I.; Arase, H.; Tsumoto, K.; Kumagai, I.; Kohda, D.; Maenaka, K. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. *J. Biol. Chem.* **2006**, *281*, 10439–10447. [[CrossRef](#)] [[PubMed](#)]
24. Alegre, E.; Rizzo, R.; Bortolotti, D.; Fernandez-Landázuri, S.; Fainardi, E.; González, A. Some basic aspects of HLA-G biology. *J. Immunol. Res.* **2014**, *2014*, 657625. [[CrossRef](#)] [[PubMed](#)]
25. Gonzalez, A.; Alegre, E.; Arroyo, A.; LeMaoult, J.; Echeveste, J.I. Identification of circulating nonclassic human leukocyte antigen G (HLA-G)-like molecules in exudates. *Clin. Chem.* **2011**, *57*, 1013–1022. [[CrossRef](#)] [[PubMed](#)]
26. Menier, C.; Saez, B.; Horejsi, V.; Martinuzzi, S.; Krawice-Radanne, I.; Bruel, S.; Le Danff, C.; Reboul, M.; Hilgert, I.; Rabreau, M.; et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: New tools to analyze the expression of nonclassical HLA class I molecules. *Hum. Immunol.* **2003**, *64*, 315–326. [[CrossRef](#)]
27. Zhao, L.; Teklemariam, T.; Hantash, B.M. Reassessment of HLA-G isoform specificity of MEM-G/9 and 4H84 monoclonal antibodies. *Tissue Antigens* **2012**, *80*, 231–238. [[CrossRef](#)]
28. Juch, H.; Blaschitz, A.; Daxböck, C.; Rueckert, C.; Kofler, K.; Dohr, G. A novel sandwich ELISA for alpha1 domain based detection of soluble HLA-G heavy chains. *J. Immunol. Methods* **2005**, *307*, 96–106. [[CrossRef](#)]
29. Poláková, K.; Železníková, T.; Russ, G. HLA-G5 in the blood of leukemia patients and healthy individuals. *Leuk. Res.* **2013**, *37*, 139–145. [[CrossRef](#)]
30. Spurny, C.; Kailayangiri, S.; Altvater, B.; Jamitzky, S.; Hartmann, W.; Wardelmann, E.; Ranft, A.; Dirksen, U.; Amler, S.; Harges, J.; et al. T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. *Oncotarget* **2018**, *9*, 6536–6549. [[CrossRef](#)]

31. Oujj-Sageshima, N.; Geraghty, D.E.; Ishitani, A.; Hatake, K.; Ito, T. Establishment of optimized ELISA system specific for HLA-G in body fluids. *HLA* **2016**, *88*, 293–299. [[CrossRef](#)]
32. Rebmann, V.; LeMaoult, J.; Rouas-Freiss, N.; Carosella, E.D.; Grosse-Wilde, H. Quantification and identification of soluble HLA-G isoforms. *Tissue Antigens* **2007**, *69* (Suppl. 1), 143–149. [[CrossRef](#)]
33. McMaster, M.; Zhou, Y.; Shorter, S.; Kapasi, K.; Geraghty, D.; Lim, K.H.; Fisher, S. HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. *J. Immunol* **1998**, *160*, 5922–5928. [[PubMed](#)]
34. Loke, Y.W.; King, A.; Burrows, T.; Gardner, L.; Bowen, M.; Hiby, S.; Howlett, S.; Holmes, N.; Jacobs, D. Evaluation of trophoblast HLA-G antigen with a specific monoclonal antibody. *Tissue Antigens* **1997**, *50*, 135–146. [[CrossRef](#)] [[PubMed](#)]
35. Fournel, S.; Huc, X.; Aguerre-Girr, M.; Solier, C.; Legros, M.; Praud-Brethenou, C.; Moussa, M.; Chaouat, G.; Berrebi, A.; Bensussan, A.; et al. Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules. *Tissue Antigens* **2000**, *55*, 510–518. [[CrossRef](#)] [[PubMed](#)]
36. Pela, F.P.; Rustiguel, J.K.; Rodrigues, L.C.; Mendonca, J.N.; Andrade, C.D.C.; Lopes, N.P.; Rosa, J.C.; Nonato, M.C.; Favier, B.; Donadi, E.A.; et al. A soluble recombinant form of human leucocyte antigen-G 6 (srHLA-G6). *Biochem. Biophys. Res. Commun.* **2017**, *487*, 28–33. [[CrossRef](#)] [[PubMed](#)]
37. Poláková, K.; Bennink, J.R.; Yewdell, J.W.; Bystrická, M.; Bandzuchová, E.; Russ, G. Mild acid treatment induces cross-reactivity of 4H84 monoclonal antibody specific to nonclassical HLA-G antigen with classical HLA class I molecules. *Hum. Immunol.* **2003**, *64*, 256–264. [[CrossRef](#)]
38. Carosella, E.D.; Moreau, P.; Lemaoult, J.; Rouas-Freiss, N. HLA-G: From biology to clinical benefits. *Trends Immunol.* **2008**, *29*, 125–132. [[CrossRef](#)]
39. Shiroishi, M.; Tsumoto, K.; Amano, K.; Shirakihara, Y.; Colonna, M.; Braud, V.M.; Allan, D.S.; Makadzange, A.; Rowland-Jones, S.; Willcox, B.; et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 8856–8861. [[CrossRef](#)]
40. Shiroishi, M.; Kuroki, K.; Rasubala, L.; Tsumoto, K.; Kumagai, I.; Kurimoto, E.; Kato, K.; Kohda, D.; Maenaka, K. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 16412–16417. [[CrossRef](#)]
41. Kuroki, K.; Matsubara, H.; Kanda, R.; Miyashita, N.; Shiroishi, M.; Fukunaga, Y.; Kamishikiryo, J.; Fukunaga, A.; Fukuhara, H.; Hirose, K.; et al. Structural and Functional Basis for LILRB Immune Checkpoint Receptor Recognition of HLA-G Isoforms. *J. Immunol.* **2019**. [[CrossRef](#)]
42. Shiroishi, M.; Kuroki, K.; Tsumoto, K.; Yokota, A.; Sasaki, T.; Amano, K.; Shimojima, T.; Shirakihara, Y.; Rasubala, L.; van der Merwe, P.A.; et al. Entropically driven MHC class I recognition by human inhibitory receptor leukocyte Ig-like receptor B1 (LILRB1/ILT2/CD85j). *J. Mol. Biol.* **2006**, *355*, 237–248. [[CrossRef](#)] [[PubMed](#)]

